BLOG

Xenothera receives approval for first in man Kidney Transplant Clinical Trial

Nantes, September 11th, 2019 – Xenothera announces it has received  Czech Republic regulatory agency approval to begin its Phase I/II clinical trial of its LIS1 product developed as induction treatment in solid organ transplantation. Xenothera plans to initiate a mono centric trial with volunteering kidney transplant patients. The clinical trial is planned at the Praha Institute for Clinical…
Lire la suite

Xenothera presents at ESOT 2019

XENOTHERA will participate at ESOT 2019 that will take place in Copenhagen in Sept.19.During the congress the preclinical data obtained with the first product, LIS1, for prevention of graft rejection, will be presented by Bernard Vanhove, COO, and Juliette Rousse, PhD student.In the first two communications, the original data obtained with LIS1 in non-human primates…
Lire la suite

Xenothera announces receivability of its Clinical Trial Application at the Czech Republic regulatory agency for a first in man clinical trial of LIS1 in kidney transplanted patients with dose escalation.

Nantes, June 21st, 2019 – Xenothera announces receivability after its submission of a Clinical Trial Application (CTA) with Czech Republic regulatory agency for a Phase I/II trial of its LIS1 product developed as induction treatment in solid organ transplantation. Upon CTA clearance, Xenothera plans to initiate a mono centric trial with volunteering kidney transplant patients. The clinical trial is…
Lire la suite

Xenothera Announces Publication in European Journal of Clinical Investigation on Immunological Mechanisms Underlining Use of LIS1

Kidney graft recipients receiving anti-lymphocyte globulins of animal origin undergo unwanted immune responses against Neu5GC carbohydrate antigens related to safety concerns, endothelial inflammation and possibly rejection. Xenothera’s LIS1 is a next-generation engineered Anti-Lymphocyte Globulins which does not elicit responses against Neu5GC carbohydrate antigens. Nantes, February 28, 2019 – Xenothera announced publication in European Journal of…
Lire la suite

XENOTHERA to raise Series A

Xenothera has started to gather investors for a Series A round of funding that will occur in 2019. This upcoming round will finance an highly anticipated first-in-human trial that will start this year. After amazing pre-clinical and toxicology data in 2018, Xenothera’s LIS1 is ready for clinical tests. As per the nature of the product…
Lire la suite

XENOTHERA sponsors the realization of a fresco for the hospital by transplanted patients

Nantes, november 2017 The fresco, more than 8 meters long, has been set up in the hall of the Institute of Transplantation of Nantes, France, where all patients, doctors and scientists meet every day. The fresco has been conceived by patients after having shared their feelings about how transplantation has changed their life course. The…
Lire la suite

XENOTHERA nominated for the Ernst&Young Entrepreneur Award

Nantes, September 2017 We have been selected for the 2017 entrepreneur awards of Ernst & Young…

Distinction: Jean-Paul SOULILLOU awarded for its international exceptional career and contribution in transplantation

August 25th, 2016 XENOTHERA, a young start-up from Nantes, is honored to announce that one of the founders of the company, Prof. Jean-Paul SOULILLOU, Emeritus at the Medicine Faculty of Nantes, has just received the MEDAWAR price in Hong Kong

Press Release: Start-up XENOTHERA closes a new capital increase above 2 million euros

June 10th, 2016 XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more than 2 million euros

XENOTHERA moved to the Medicine Faculty of Nantes

September 1st, 2015 The Medicine Faculty of Nantes is welcoming the start-up biotech XENOTHERA in its facility. The company will be from now based in the Medicine University, in the neighbourhood of laboratories, biotechs, and of the Centre Hospitalo-Universitaire. New address: XENOTHERA – Faculté de Médecine – 1 rue Gaston Veil – 44 035 Nantes Cedex